{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:22:24Z","timestamp":1790022144036,"version":"4.0.1"},"reference-count":63,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004035","name":"Jordan University of Science and Technology","doi-asserted-by":"publisher","award":["20190255"],"award-info":[{"award-number":["20190255"]}],"id":[{"id":"10.13039\/501100004035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The efficacy of statins as anti-cancer drugs has been demonstrated in several malignancies but has been poorly investigated in hematological malignancies (HM). By studying its effect on oncogenic miRNAs, we investigated the effect of statin therapy on HM patients. The data were used to identify enriched pathways that were altered due to statin treatment. The main aim of this study was to identify significantly differentially expressed miRNAs and involved regulatory pathways post-atorvastatin treatment in HM patients. A panel of 95 plasma circulating miRNAs involved in tumorigenesis, apoptosis, and differentiation were relatively quantified using qPCR for blood samples obtained from 12 HM patients, 4 with Chronic Myeloid Leukemia (CML), 4 with Non-Hodgkin Lymphoma (NHL), and 4 with Essential Thrombocythemia. Pre- and post-administration of a 6-week atorvastatin course miRNA expression levels were measured. Significantly differentially expressed miRNAs were those with a fold change &gt;2 or &lt;0.5 using the Livak method with a two-sided p-value &lt; 0.05. To further understand the underlying mechanism of statin regulated miRNA, GO and KEGG pathway enrichment analyses were conducted for identified target genes using the DAVID 6.8 bioinformatics tool. Out of 95 miRNAs, 14 exhibited significant fold changes post-treatment with statins including miR-198, miR-29a+b+c, miR-204, miR-222, miR-224, miR-155, miR-128b, miR-296, miR-199a+b, miR-194, miR-125a, miR-200a, and the let-7-family that were upregulated and miR-150 that was downregulated post-statin treatment. Higher mir-222, mir-194, mir-128b, and mir-199b expressions were significantly associated with better overall survival using the Cancer Genomic Atlas leukemia and lymphoma patient cohorts. Enrichment analysis identified the PI3k-Akt pathway as well as other pathways involved in the epithelial\u2013mesenchymal transition. Atorvastatin upregulated several tumor suppressor genes involved in mediating better prognosis. The data can be used to enhance personalized treatments for patients with hematological malignancies by helping to predict the different pathways that may be targeted and, therefore, result in better survival outcomes in these patients.<\/jats:p>","DOI":"10.3390\/biom14121559","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T04:01:37Z","timestamp":1733716897000},"page":"1559","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Effect of Atorvastatin on Oncogenic miRNAs in Hematological Malignancies: A Central Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Jood","family":"Hashem","sequence":"first","affiliation":[{"name":"Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Alsukhni","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0068-5201","authenticated-orcid":false,"given":"Hassan","family":"Abushukair","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-6663","authenticated-orcid":false,"given":"Mahmoud","family":"Ayesh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2008). WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, IARC."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.2007-0228","article-title":"Battling the hematological malignancies: The 200 years\u2019 war","volume":"13","author":"Lichtman","year":"2008","journal-title":"Oncologist"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrc3907","article-title":"Haematological malignancies: At the forefront of immunotherapeutic innovation","volume":"15","author":"Bachireddy","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-017-0453-8","article-title":"Immunotherapy in hematologic malignancies: Past, present, and future","volume":"10","author":"Im","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/path.2669","article-title":"Targeted therapy in haematological malignancies","volume":"220","author":"Hamilton","year":"2010","journal-title":"J. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ma, H., Mallampati, S., An, G., and Wang, J. (2015). Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/157570"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Patlak, M. (2002). Targeting leukemia: From bench to bedside. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol., 16.","DOI":"10.1096\/fj.16.3.273e"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11899-009-0020-7","article-title":"Allogeneic hematopoietic stem cell transplantation for adult acute lymphocytic leukemia","volume":"4","author":"Terwey","year":"2009","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0268-960X(94)90111-2","article-title":"Treatment of hematological malignancies relapsing after allogeneic bone marrow transplantation","volume":"8","author":"Boiron","year":"1994","journal-title":"Blood Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6604510","article-title":"Resistance to chemotherapy: New treatments and novel insights into an old problem","volume":"99","author":"Raguz","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-014-2236-4","article-title":"HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: What is the current evidence?","volume":"94","author":"Bockorny","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","article-title":"Pharmacological actions of statins: A critical appraisal in the management of cancer","volume":"64","author":"Gazzerro","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Markowska, A., Antoszczak, M., Markowska, J., and Huczy\u0144ski, A. (2020). Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120422"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2174\/138161209787315684","article-title":"Statins and cardiovascular diseases: From cholesterol lowering to pleiotropy","volume":"15","author":"Zhou","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-018-1066-z","article-title":"Statin drugs to reduce breast cancer recurrence and mortality","volume":"20","author":"Beckwitt","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.5306\/wjco.v11.i8.573","article-title":"Statins in risk-reduction and treatment of cancer","volume":"11","author":"Barbalata","year":"2020","journal-title":"World J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yi, X., Jia, W., Jin, Y., and Zhen, S. (2014). Statin use is associated with reduced risk of haematological malignancies: Evidence from a meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087019"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cam4.411","article-title":"Statins use and the risk of all and subtype hematological malignancies: A meta-analysis of observational studies","volume":"4","author":"Pradelli","year":"2015","journal-title":"Cancer Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0195-668X(02)00419-0","article-title":"Statin effects beyond lipid lowering-are they clinically relevant?","volume":"24","author":"Bonetti","year":"2003","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cell.2007.12.024","article-title":"Getting to the root of miRNA-mediated gene silencing","volume":"132","author":"Eulalio","year":"2008","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-pathol-012513-104715","article-title":"MicroRNAs in cancer","volume":"9","author":"Garofalo","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cell.2009.02.005","article-title":"MicroRNAs and cancer: Short RNAs go a long way","volume":"136","author":"Ventura","year":"2009","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Khan, I.A., Rashid, S., Singh, N., Rashid, S., Singh, V., Gunjan, D., Das, P., Dash, N.R., Pandey, R.M., and Chauhan, S.S. (2021). Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-82266-5"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","article-title":"Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tsai, H.P., Huang, S.F., Li, C.F., Chien, H.T., and Chen, S.C. (2018). Differential microRNA expression in breast cancer with different onset age. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191195"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.2147\/OTT.S263934","article-title":"Serum Exosomal miR-1290 is a Potential Biomarker for Lung Adenocarcinoma","volume":"13","author":"Wu","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shi, Y., Zhuang, Y., Zhang, J., Chen, M., and Wu, S. (2020). Identification of Tumorigenic and Prognostic Biomarkers in Colorectal Cancer Based on microRNA Expression Profiles. BioMed Res. Int., 2020.","DOI":"10.1155\/2020\/7136049"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gablo, N., Trachtova, K., Prochazka, V., Hlavsa, J., Grolich, T., Kiss, I., Srovnal, J., Rehulkova, A., Lovecek, M., and Skalicky, P. (2020). Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082440"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.blre.2014.09.005","article-title":"Drug resistance-related microRNAs in hematological malignancies: Translating basic evidence into therapeutic strategies","volume":"29","author":"Xie","year":"2015","journal-title":"Blood Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"60723","DOI":"10.18632\/oncotarget.11032","article-title":"Role of micro-RNAs in drug resistance of multiple myeloma","volume":"7","author":"Abdi","year":"2016","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13148-018-0587-8","article-title":"The role and mechanisms of action of microRNAs in cancer drug resistance","volume":"11","author":"Si","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.semcancer.2021.03.014","article-title":"miRNAs mediated drug resistance in hematological malignancies","volume":"83","author":"Caires","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3892\/ijo.2012.1647","article-title":"Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer (Review)","volume":"41","author":"Allegra","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/CCO.0000000000000657","article-title":"Targeting microRNA in hematologic malignancies","volume":"32","author":"Han","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chaplin, M., Kirkham, J.J., Dwan, K., Sloan, D.J., Davies, G., and Jorgensen, A.L. (2020). STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003344"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2013). Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N. Engl. J. Med., 368, 2059\u20132074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"ref_41","unstructured":"IBM Corp (2019). IBM SPSS Statistics for Windows, IBM."},{"key":"ref_42","unstructured":"GraphPad Software (2021). GraphPad Prism, GraphPad Software."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1517\/14740331003662620","article-title":"Statin use and cancer risk: A comprehensive review","volume":"9","author":"Boudreau","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/0973-1482.98967","article-title":"The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: A comprehensive review","volume":"8","author":"Zeichner","year":"2012","journal-title":"J. Cancer Res. Ther."},{"key":"ref_45","first-page":"1055","article-title":"Potential antitumor effects of statins (Review)","volume":"23","author":"Jakobisiak","year":"2003","journal-title":"Int. J. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.tips.2018.09.005","article-title":"MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy","volume":"39","author":"Mohajeri","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2015.10.003","article-title":"Exploring miRNA based approaches in cancer diagnostics and therapeutics","volume":"98","author":"Mishra","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.3748\/wjg.v20.i33.11727","article-title":"MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer","volume":"20","author":"Stiegelbauer","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s13346-013-0160-0","article-title":"Overcoming obstacles in microRNA delivery towards improved cancer therapy","volume":"4","author":"Markovsky","year":"2014","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jconrel.2013.09.015","article-title":"Progress in microRNA delivery","volume":"172","author":"Zhang","year":"2013","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgz183","article-title":"miR-155 as a novel clinical target for hematological malignancies","volume":"41","author":"Witten","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3324\/haematol.2011.046888","article-title":"Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA\u2014Target gene interactions in acute myeloid leukemia","volume":"96","author":"Russ","year":"2011","journal-title":"Haematologica"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Jones, S. (2004). An overview of the basic helix-loop-helix proteins. Genome Biol., 5.","DOI":"10.1186\/gb-2004-5-6-226"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11667","DOI":"10.1007\/s13277-016-5144-5","article-title":"The dual regulatory role of miR-204 in cancer","volume":"37","author":"Li","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7150\/ijbs.23230","article-title":"The role of TGF-\u03b2\/SMAD4 signaling in cancer","volume":"14","author":"Zhao","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","article-title":"Mechanisms of TGF-beta signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"964","DOI":"10.7150\/ijbs.4564","article-title":"Complexities of TGF-\u03b2 targeted cancer therapy","volume":"8","author":"Connolly","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/leu.2016.279","article-title":"Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia","volume":"31","author":"Narayan","year":"2017","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.canep.2012.07.002","article-title":"Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia","volume":"36","author":"Ishihara","year":"2012","journal-title":"Cancer Epidemiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/bloodadvances.2018029660","article-title":"MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma","volume":"3","author":"Due","year":"2019","journal-title":"Blood Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2119\/molmed.2014.00214","article-title":"Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia","volume":"21","author":"Stamatopoulos","year":"2015","journal-title":"Mol. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.gene.2017.05.030","article-title":"Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression","volume":"626","author":"Zhou","year":"2017","journal-title":"Gene"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/1389201015666140519122524","article-title":"Effect of miR-128 in DNA damage of HL-60 acute myeloid leukemia cells","volume":"15","author":"Seca","year":"2014","journal-title":"Curr. Pharm. Biotechnol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/12\/1559\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:49:29Z","timestamp":1760114969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/12\/1559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":63,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["biom14121559"],"URL":"https:\/\/doi.org\/10.3390\/biom14121559","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,7]]}}}